SAN DIEGO, July 10, 2018 /PRNewswire-iReach/
SignalRx Pharmaceuticals Inc., a clinical-stage company developing novel small-molecules therapeutics via in-silico design to simultaneously inhibit multiple key orthogonal and synergistic oncotargets for the treatment of cancer, is pleased to announce that the United States Patent and Trademark Office has issued US Patent 9,981,983, entitled "Thienopyranones As Kinase Inhibitors".
This patent, together with existing US and World patents issued, provides further protection to the scaffold platform SignalRx has for the development of safer and more efficacious immuno-oncology targeted therapeutics.
"Our thienopyranone (TP) scaffold provides an excellent molecular platform to inhibit key immuno-oncology driving targets and we have developed the expertise using our proprietary in silico CRIMP technology to engineer our TP scaffold to inhibit carefully selected targets that result in synthetic lethality. And we have already proven and published how our TP multi-target approach provides safer anticancer agents that in vivo avoid the common unwanted toxicity and side effects that results from combining 2 individual agents, a common problem faced in combo therapeutics" said Dr. Joseph Garlich, SignalRx's Chief Scientific Officer.
SignalRx is seeking partnering opportunities to accelerate the development of its programs and advance novel anticancer therapeutics into first-in-man clinical trials based on the promising profile and mode of action of its inhibitors. Since these are single molecules with a single PK/PD and toxicity profile, there is a great opportunity to streamline their development alone and in combination therapies.
About SignalRx Pharmaceuticals Inc.
SignalRx is a privately held corporation based in San Diego, CA developing small molecule inhibitors of key signaling pathways in cancer and cancer stem cells. The company has developed its proprietary CRIMP technology platform to develop new small-molecule therapeutics against more than one target molecule selected from the discovery of synthetic lethalities in cancer cells, epigenetic regulatory processes, immune checkpoints and DNA repair actions. SignalRx's research programs have novel dual inhibitors targeting critical onco-targets such as PI3K, MEK, BRAF, IDO1, IDH1, CDK4/6, Wnt, HDAC, DNMT, PARP and BET bromodomains. SignalRx is leveraging its expertise in novel multi-action inhibitors to develop enhanced anticancer therapeutics with improved efficacy, novel mechanism of action in a single molecule, and the potential to streamline their development (single agent, combination therapies).
Media Contact: Guillermo Morales MBA, PhD, SignalRx Pharmaceuticals Inc., 520-777-9609, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE SignalRx Pharmaceuticals Inc.